NDAINTRAVENOUSSOLUTION
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
6/8 — Strong
ANGIOMAX RTU (bivalirudin) by MAIA Biotechnology is thrombin inhibitors [moa]. Approved for coronary artery disease, acute coronary syndrome, myocardial infarction. First approved in 2019.
Drug data last refreshed Yesterday
Mechanism of Action
Thrombin Inhibitors
Pharmacologic Class:
Anti-coagulant
Indications (3)
Worked on ANGIOMAX RTU at MAIA Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.